Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers

SOFAR

Status and phase: Completed; Phase 1

Conditions: Healthy Adult Male Volunteers

Treatments: Drug: Beclomethasone dipropionate

Study type: Interventional

Funder types: Industry

Identifiers

NCT04873063

PSC DS BDP-Once 1

Details and patient eligibility

About

Single-centre, randomized, double-blind, two-period, two-sequence, cross-over 7-day study.

This study is the first safety/tolerability evaluation of a product -suppository formulation containing 6 mg BDP (once daily dosing), a second-generation oral or rectal corticosteroids with high topical anti-inflammatory efficacy in the gut and minimal systemic bioavailability (BA).

BDP is marketed in different pharmaceutical formulations, including 3 mg suppositories, and approved for ulcerative proctosigmoiditis in the first attack or exacerbation phase at the dosage of 3 mg twice a day. For these reasons, a 6 mg suppository (Test - "T" product) is a scale-up of the 3 mg formulation (Reference - "R" product).

For locally-applied-locally acting drug products that result in quantifiable systemic availability due to absorption from the administration site, relative systemic BA is informative for safety, but also with respect to efficacy. Therefore, safety/tolerability of T is evaluated through a comparison to R.

Full description

Primary objective is the evaluation of systemic safety of T, based on valid surrogate outcomes - systemic BA (relative BA) at the start of treatment (first 24 hours) and after 7 days of continuous treatment; effects on the hypothalamo-pituitary-adrenal axis (HPA) assessed based on 24-hour cortisol profile after 7 days of continuous treatment. This includes identification of subjects with cortisol levels <10 μg/dL at the last sampling point in the 24-hour cortisol profile (08:00 a.m. on Day 8). In such cases, identified subjects will undergo ACTH stimulation test in the morning of Day 9.

Secondary objective is the evaluation of safety/tolerability based on clinical and laboratory adverse events.

Enrollment: 28 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male, aged between 18 and 55 years. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory and other (e.g. ECG) tests.
• BMI 19.0 - 29.0 kg/m2;
• Signed and dated written informed consent of the subject to participate in the clinical study;
• The subject is willing to refrain from the use of illicit drugs and alcohol and to adhere to other protocol-stated restrictions while participating in the study;
• The subject is able to understand and comply with the protocol requirements and instructions and is likely to complete the study as planned;
• Non-smoker for at least 3 months.

Exclusion criteria

• Subject with a significant abnormality in the past and/or at the Screening that influences the present general health condition and requires pharmacological treatment during the study;
• History of serious allergic diseases, including allergy to medicinal products, which in opinion of the investigator, contraindicates participation to the trial;
• History of diseases of the alimentary tract, liver or kidneys that may influence absorption, distribution and elimination;
• History of average alcohol consumption;
• Hypersensitivity to BDP or study products inactive ingredients;
• Use of any pharmacological treatments (including high dose vitamins, lozenges, herbal and dietary supplements), with the exception of paracetamol ≤ 1 g/daily, within 15 days before the admission to the study Site in the Period 1;
• Use of steroids, anabolic or hormonal therapy within 3 months before the admission to the study Site in the Period 1;
• Laboratory indication of adrenocortical dysfunction;
• Blood loss exceeding 200 ml over the last 4 weeks before the day of Screening;
• Positive results to Sars Cov-2 nasopharyngeal swab;
• Positive results of HBsAg, anti-HCV, anti-HIV tests;
• Blood pressure: systolic >140mmHg or < 90mmHg, diastolic <60 mmHg or >90 mmHg during screening procedures;
• Subject who adhere to a special diet (e.g. low calories, vegetarian etc.);
• Consumption of products containing methylxanthines in the following average quantities: > 3 cups of 200 ml of strong coffee a day;
• Presence of metabolites of illicit drugs (opioids, cannabis) during screening procedures;
• Participation in other clinical trials during the 6 months preceding the study, counting from the day of last product administration.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

28 participants in 2 patient groups

Reference/Test

Experimental group

Description:

* 3 mg BDP suppositories (R product) delivered twice daily for 7 days * Washout period (at least 7-day and preferably no more than 9 days) * 6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.

Treatment:

Drug: Beclomethasone dipropionate

Test/Reference

Experimental group

Description:

* 6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product. * Washout period (at least 7-day and preferably no more than 9 days) * 3 mg BDP suppositories (R product) delivered twice daily for 7 days

Treatment:

Drug: Beclomethasone dipropionate